Historically, managing C3G relied on off-label immunosuppressive agents and corticosteroids, which offered limited disease-specific efficacy. While the recent approvals of Fabhalta and Empaveli/Aspaveli provided the first targeted options, these therapies carry significant safety warnings regarding life-threatening bacterial infections. This clinical gap has left patients and providers seeking safer, more convenient alternatives, particularly those that might eventually offer oral administration.
New Pipeline Drugs Target $1 Billion Complement 3 Glomerulopathy Market
The treatment landscape for Complement 3 Glomerulopathy (C3G) is undergoing a significant shift as pharmaceutical developers race to move beyond traditional immunosuppressants. With the global market valued at approximately $1 billion in 2025, four distinct investigational therapies are emerging to challenge recently approved standards of care.
DelveInsight projects the C3G market across the 7MM region will grow at a 28% compound annual growth rate through 2036. Current development efforts are focused on novel mechanisms:
- Zaltenibart (Novo Nordisk/Omeros): A MASP-3 inhibitor that recently gained Rare Pediatric Disease Designation.
- KP104 (Kira Pharmaceuticals): A bifunctional biologic designed to inhibit both alternative and terminal complement pathways simultaneously.
- ARO-C3 (Arrowhead Pharmaceuticals): An RNAi therapeutic that reduces liver-derived C3 production.
- CPV-104 (Eleva): A recombinant human Factor H therapy currently undergoing clinical evaluation to clear kidney C3 deposits.
Comments (0)
No comments yet. Be the first!